TICKERNERD
Menu
GRALGRALHealthcare · Diagnostics & Research

GRAL Stock Forecast: GRAIL, Inc. Price Predictions for 2026-2027

Last close, 4 Sept 2026
$80
−0.35% on the day

The 9 Wall Street analysts covering GRAIL, Inc. hold a median 12-month price target of $75 — -7.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 7 Sept 2026 — in the lower half.

Market cap
$3.6B
Ticker Nerd rank
38 / 100
Median analyst target
$75
Analysts covering
9
Revenue$44.7M+25.7% y/y
Operating income−$148.4M
Net income−$110.2M
Free cash flow−$81.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.4%
1M
+10.5%
YTD
−6.1%
1Y
+139.2%
From 52W high
−30.8%
From 52W low
+139.2%
$34
$116
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GRAL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores GRAIL, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Sept 2026
38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
79
Revisions
77
Accruals
59
Growth
53
Size
28
Quality
27
Value
27
Issuance
23
Volatility
22

Momentum (79): The shares have been drifting up relative to others.

Volatility (22): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GRAL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GRAL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100$120Oct 25Jan 26Apr 26Jul 26GRALHigh $88Median $75Low $60

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
4 Buy5 Hold0 Sell
Low $60Median $75High $88

The green dot is the last close — the median target sits −7.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 July 2026MizuhoMaintainsNeutral$58 → $65
5 June 2026Goldman SachsInitiatesNeutral$60
5 June 2026Goldman SachsInitiatesNeutral—
6 May 2026Piper SandlerMaintainsNeutral—
6 May 2026TD CowenMaintainsBuy—
10 Apr 2026MizuhoInitiatesNeutral—
10 Apr 2026Piper SandlerInitiatesNeutral—
30 Mar 2026GuggenheimMaintainsBuy—
24 Feb 2026Morgan StanleyMaintainsEqual-Weight—
20 Feb 2026BairdMaintainsOutperform—
20 Feb 2026Canaccord GenuityMaintainsBuy—
17 Feb 2026BairdInitiatesOutperform—
26 Jan 2026GuggenheimMaintainsBuy—
2 Dec 2025Morgan StanleyMaintainsEqual-Weight—
17 Nov 2025Canaccord GenuityMaintainsBuy—
12 Nov 2025GuggenheimUpgradeBuy—
22 Oct 2025Canaccord GenuityMaintainsBuy—
3 Oct 2025Canaccord GenuityMaintainsBuy—
14 May 2025Canaccord GenuityMaintainsBuy—
21 Apr 2025Canaccord GenuityInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GRAL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

GRAL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Sept 2026, GRAIL, Inc. returned +139.2% against +20.0% for the S&P 500, dividends included.

GRAL vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300350Oct 25Jan 26Apr 26Jul 26GRALS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GRAL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

GRAIL, Inc. (GRAL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.2×

Cheaper than 91% of US stocks

Price / sales
21.7×

Cheaper than 9% of US stocks

Price / book
1.4×

Cheaper than 59% of US stocks

EV / EBITDA
−7.4×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
25.7%

Higher than 75% of US stocks

Earnings growth (YoY)
25.7%

Higher than 63% of US stocks

Gross margin
−28.1%

Higher than 3% of US stocks

Operating margin
−332.0%

Higher than 9% of US stocks

Net margin
−236.9%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−16.1%

Higher than 33% of US stocks

Return on assets
−12.0%

Higher than 25% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

GRAIL, Inc. (GRAL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • GRAIL, Inc. has a market value of $3.6B and an enterprise value of $2.8B.

  • Revenue in the twelve months to 30 June 2026: $165.3M. The latest quarter grew 25.7% year on year.

  • Net income over the same four quarters: −$391.6M, a −236.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−9.75.

  • Free cash flow in the twelve months to 30 June 2026: −$296.2M.

  • Shares outstanding: 44.7M.

  • Trailing P/E: −7.2×; forward P/E: −8.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • GRAIL, Inc. employs 910 people — $182K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

GRAL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
GRALGRAIL, Inc.$3.6B
38
VCYTVeracyte, Inc.$3.4B
95
ADPTAdaptive Biotechnologies Corp.$3.9B
74
BLLNBillionToOne, Inc.$4.7B
15
CDNACareDx, Inc.$2.6B
99
WGSGeneDx Holdings Corp.$2.5B
43
SHCSotera Health Co.$5.4B
97

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own GRAIL, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GRAL news & analysis

Grail Stock Jumps in August as FDA Schedules a Key Meeting for its Galleri Cancer Test

The Motley Fool · 4 Sept 2026positive

Grail's stock rose in August after the FDA scheduled a key meeting concerning its Galleri multi-cancer early detection test. The company received favorable news from the FDA, and the upcoming pivotal meeting is seen as important for the test's regulatory path.

Why it matters — FDA approval is seen as crucial for Galleri's adoption by insurers, so this upcoming pivotal meeting could be a significant catalyst for Grail.

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PRNewsWire · 3 Sept 2026neutral

GRAIL, Inc. announced it granted restricted stock units underlying an aggregate of 55,867 shares of common stock to 59 recently hired non-executive employees. The equity awards serve as an inducement material to their acceptance of employment with GRAIL, issued under Nasdaq Listing Rule 5635(c)(4).

Why it matters — This discloses the company's equity compensation actions for newly hired employees, which is relevant for investors tracking GRAL's share dilution and hiring activity.

GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference

PRNewsWire · 31 Aug 2026neutral

GRAIL, Inc. announced that company management will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 14 at 11:30 a.m. The presentation was announced via a press release on August 31, 2026.

Why it matters — A presentation at a major healthcare conference gives GRAIL an opportunity to brief investors and industry participants on its cancer-detection business.

GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting

MarketBeat · 14 Aug 2026positive

GRAIL Chief Financial Officer Aaron Freidin said the company's Galleri multi-cancer early detection test saw strong first-half growth as it expanded distribution through digital health platforms, employers, and physician offices. The comments come ahead of a key FDA advisory meeting on the test.

Why it matters — A GRAL watcher would care because strong Galleri growth and expanded distribution suggest momentum ahead of a significant regulatory milestone for the company's core product.

GRAIL: Looking Beyond The NHS-Galleri Headline

Seeking Alpha · 12 Aug 2026negative

GRAIL faces a binary FDA approval decision for its Galleri test that is expected to drive significant stock movement. The piece notes disappointing NHS-Galleri trial results, argues the test's value may have shown with a longer monitoring period, and warns that commercialization delays could force the company to raise capital on unfavorable terms despite a solid cash position.

Why it matters — A GRAL watcher would care because this update outlines both a pivotal upcoming FDA catalyst for Galleri and a notable risk of dilutive capital raising amid commercialization delays.

FAQ

Frequently asked questions about GRAL stock

What is the GRAL stock price forecast for 2026-2027?

The 9 Wall Street analysts covering GRAIL, Inc. have a median 12-month price target of $75, with estimates ranging from $60 to $88. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GRAL stock a buy right now?

Of the 9 analysts covering GRAIL, Inc., 4 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GRAIL, Inc. 38 out of 100 across roughly 4,600 US stocks as at 7 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GRAL?

As at 7 Sept 2026, GRAIL, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (79 of 100).

Will GRAL stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies -7.3% from the last close, and Ticker Nerd's factor model ranks GRAIL, Inc. 38 out of 100 as at 7 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GRAL stock forecast for 2030?

No analyst covering GRAIL, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GRAL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $60 to $88 over the next 12 months.

How has GRAL stock performed over the past year?

GRAIL, Inc. returned +139.2% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does GRAIL, Inc. do?

GRAIL, Inc. is a commercial-stage healthcare company focused on multi-cancer early detection testing and services.

What is the latest news on GRAL?

The most recent item we track (The Motley Fool, 4 Sept 2026): "Grail Stock Jumps in August as FDA Schedules a Key Meeting for its Galleri Cancer Test". Grail's stock rose in August after the FDA scheduled a key meeting concerning its Galleri multi-cancer early detection test. The company received favorable news from the FDA, and the upcoming pivotal meeting is seen as important for the test's regulatory path.

Company

About GRAIL, Inc.

GRAIL, Inc. is a commercial-stage healthcare company focused on multi-cancer early detection testing and services. Its core offering is Galleri, a blood-based screening test designed to detect multiple cancer types before symptoms appear, supporting earlier clinical evaluation and diagnosis. The company uses next-generation sequencing, machine learning, software, and automation to analyze biological signals associated with cancer and deliver screening insights through laboratory and service workflows. GRAIL serves healthcare providers and patients in the United States and international markets, with its work centered on cancer screening, diagnostic support, and related laboratory services. Headquartered in Menlo Park, California, GRAIL plays a notable role in the expanding field of liquid biopsy and genomic diagnostics, where it contributes to efforts aimed at improving early cancer detection and broadening access to advanced screening technologies.

CEO Dr. Joshua J. Ofman M.D., M.S.H.S · 910 employees · United States · https://grail.com